Sjögren's disease & overlap diseases
Sjögren’s disease metabolome reveals biomarker signatures to characterise patients and assess disease activity
Authors' conclusion
A plasma metabolome biomarker signature was developed that can be implemented in clinical studies by simple blood collection. The biomarker signature allows to characterise disease activity of patients with SjD at baseline
Study context
- Population
- Patients with sjögren's disease (SjD) and healthy subjects from two independent cohorts, Poland (PL) and the UK; saliva, tears and plasma samplestwo cohorts (PL, UK)
- Exposure
- Patients with SjD vs healthy subjects
- Outcome
- Metabolome of SjD
Methodological detailstwo independent cohorts, longitudinal samples (UK cohort), mass spectrometry screening platform, Mass spectrometry screening platform with 4500 reference metabolites
- Two independent cohorts
- Longitudinal samples (UK cohort)
- Mass spectrometry screening platform
- Mass spectrometry screening platform with 4500 reference metabolites
Main finding
As reported in the abstract
- Patient heterogeneity reflected in the metabolome across plasma, saliva and tears, with consistent disturbances in amino acid metabolism and transport pathway
- Biomarker signature developed using both cohorts allowed characterisation of patients with milder and more severe disease activity
- Signature includes metabolites linked to gamma-glutamyl cycle, pyrimidine metabolism and sex steroid hormones
Observational data: associations, not effects.
Original publication
Sjögren’s disease metabolome reveals biomarker signatures to characterise patients and assess disease activity. RMD Open. Published 5 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →